Boundless Bio, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The company is a clinical-stage precision oncology company developing therapies directed at extrachromosomal DNA (ecDNA). It has no approved products and has generated no product revenue.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $13.1 million | $9.5 million | +$3.6 million |
| General and administrative expense | $3.8 million | $2.6 million | +$1.2 million |
| Total operating expenses / operating loss | $16.9 million / $(16.9) million | $12.1 million / $(12.1) million | Expenses increased $4.8 million |
| Interest and other income, net | $1.5 million | $0.4 million | +$1.1 million |
| Net loss | $(15.4) million | $(11.7) million | Loss increased $3.7 million |
| Net loss per share, basic and diluted | $(12.27) | $(9.91) | Loss per share increased |
| Net cash used in operating activities | $(15.8) million | $(12.1) million | Cash use increased $3.7 million |
Margins are not meaningful because the company had no revenue. R&D expense growth reflected increased program spending, personnel and third-party services; G&A growth included higher personnel, stock compensation and professional fees. Higher interest income reflected the larger investment portfolio and market yields.
At March 31, 2024, cash and cash equivalents were $25.1 million, short-term investments were $79.7 million, and cash, cash equivalents and short-term investments totaled $104.9 million. Total assets were $117.1 million; current liabilities were $10.6 million; accumulated deficit was $151.5 million. The filing reports no borrowings or interest-bearing debt. Q1 operating cash use was partly offset by $18.1 million of net investing cash inflow, primarily investment maturities.
On April 2, 2024, after quarter-end, the company completed its IPO of 6.25 million shares at $16 per share, receiving approximately $87.7 million in net proceeds. Preferred stock converted into 14.74 million common shares. Management says existing resources plus IPO proceeds are expected to fund operations into the second half of 2026; this estimate depends on assumptions and actual spending may differ. The financial statements as of March 31 do not include the IPO.
Material changes and notable items
- Operating expenses rose 39.7% year over year, while net loss increased 31.7%. R&D increased by $3.6 million, with higher direct program costs for BBI-355, BBI-825 and other programs, as well as indirect personnel and outside-service costs.
- Operating cash use increased year over year, mainly due to higher personnel and third-party development spending.
- The company effected a one-for-19.5 reverse stock split on March 19, 2024; share and per-share figures are retrospectively adjusted in the filing.
- Deferred IPO offering costs were $5.3 million at March 31, 2024. They were applied against IPO proceeds at closing.
- Aggregate future operating lease commitments were $73.5 million. The planned approximately 80,000-square-foot facility lease has a 120-month term; occupancy was estimated for October 2024, subject to construction and delivery. The company’s existing lease was expected to end shortly after commencement of the new lease.
Outlook, risks and contingencies
- Management expects continued and increasing losses as it advances clinical and preclinical programs, develops its diagnostic, expands operations and incurs public-company costs. Additional financing will likely be needed beyond current resources; no other committed funding source is disclosed.
- For BBI-355, an oral CHK1 inhibitor in the Phase 1/2 POTENTIATE trial, management expects preliminary safety and antitumor-activity data in the second half of 2024, from approximately 50–90 patients across single-agent and combination cohorts.
- For BBI-825, an oral RNR inhibitor in the Phase 1/2 STARMAP trial, management expects preliminary combination data in the second half of 2025. A third, discovery-stage program targets a kinesin involved in ecDNA segregation; the company expects to submit an IND in the first half of 2026.
- The ecDNA-directed approach is unproven, and both clinical programs are early-stage. Key risks include clinical safety or efficacy failures, enrollment and trial delays, diagnostic development, regulatory approval, competition, intellectual-property protection, reliance on third-party manufacturers and CROs, and the need for additional capital.
- The company relies on third parties for manufacturing and has no manufacturing facilities. The new facility lease and its timing, tenant-improvement allowance and related payments are material commitments.
- No material litigation was reported, and no litigation liabilities were accrued. The company reported no material proceedings and no defaults upon senior securities.
- Management concluded disclosure controls and procedures were effective as of March 31, 2024. Management was not yet required to assess internal control over financial reporting; the filing says that assessment is expected after the 2025 Form 10-K.
Important facts for investors to verify
- Whether the IPO proceeds and cash runway remain consistent with management’s stated expectation of funding operations into the second half of 2026, given the pace of clinical, R&D and facility spending.
- Progress, enrollment, safety findings and timing of the BBI-355 and BBI-825 trial readouts, and whether preliminary results support further development.
- Delivery and commencement timing, occupancy costs and cash commitments associated with the approximately $73.5 million of aggregate lease obligations.
- Whether the ecDNA diagnostic and third-party manufacturing arrangements can support the company’s clinical plans, and whether additional financing or dilution will be required.